TECENTRIQ® NOW HAS 5 APPROVALS IN LUNG CANCER
A new option in PD-L1-high 1L metastatic NSCLC

### TECENTRIQ Lung Cancer Indications*

<table>
<thead>
<tr>
<th>NEW APPROVAL</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Metastatic Non-Small Cell Lung Cancer</strong></td>
<td>TECENTRIQ, as a single agent, is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1–stained ≥50% of tumor cells [TC ≥50%] or PD-L1–stained tumor-infiltrating immune cells [IC] covering ≥10% of the tumor area [IC ≥10%]), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.</td>
</tr>
<tr>
<td></td>
<td>TECENTRIQ, in combination with bevacizumab, paclitaxel, and carboplatin, is indicated for the first-line treatment of adult patients with metastatic nonsquamous, non-small cell lung cancer (nsqNSCLC) with no EGFR or ALK genomic tumor aberrations.</td>
</tr>
<tr>
<td></td>
<td>TECENTRIQ, in combination with paclitaxel protein-bound and carboplatin, is indicated for the first-line treatment of patients with metastatic nsqNSCLC with no EGFR or ALK genomic tumor aberrations.</td>
</tr>
<tr>
<td></td>
<td>TECENTRIQ is indicated for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ.</td>
</tr>
<tr>
<td><strong>Extensive-Stage Small Cell Lung Cancer</strong></td>
<td>TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).</td>
</tr>
</tbody>
</table>

*Please refer to accompanying Prescribing Information for a complete list of TECENTRIQ indications.

### Important Safety Information

Serious and sometimes fatal adverse reactions occurred with TECENTRIQ treatment. Warnings and precautions include immune-mediated serious adverse reactions, including pneumonitis, hepatitis, colitis, endocrinopathies, and other immune-mediated adverse reactions. Other warnings and precautions include infections, infusion-related reactions, and embryo-fetal toxicity.

Please see accompanying full Prescribing Information and additional Important Safety Information throughout this resource.
**Patient Assistance Information**

Genentech Oncology Access Solutions offers a range of access and reimbursement support to help patients begin treatment as soon as possible. We can help your patients by providing:

- Benefits investigations (BIs)
- Prior authorization (PA) resources
- Information about authorized specialty pharmacies (SPs) and specialty distributors
- Sample billing and coding information
- Resources for denials and appeals
- Patient assistance options

**Important Safety Information (cont’d)**

**Serious Adverse Reactions**

- **Immune-mediated pneumonitis.** Immune-mediated pneumonitis or interstitial lung disease, including fatal cases, have occurred. Permanently discontinue TECENTRIQ for Grade 3 or 4 pneumonitis
- **Immune-mediated hepatitis.** Immune-mediated hepatitis and liver test abnormalities, including fatal cases, have occurred. Permanently discontinue TECENTRIQ for AST or ALT elevations more than 8 times the upper limit of normal or total bilirubin more than 3 times the upper limit of normal

Please see accompanying full Prescribing Information and additional Important Safety Information throughout this resource.
Important Safety Information (cont’d)

- **Immune-mediated colitis.** Immune-mediated diarrhea or colitis have occurred. Permanently discontinue TECENTRIQ for Grade 4 diarrhea or colitis
- **Immune-mediated endocrinopathies.** Thyroid disorders, adrenal insufficiency, type 1 diabetes mellitus, including diabetic ketoacidosis, and hypophysitis/hypopituitarism have occurred
- **Other immune-mediated adverse reactions.** TECENTRIQ can cause severe and fatal immune-mediated adverse reactions. These immune-mediated reactions may involve any organ system. Permanently discontinue TECENTRIQ for Grade 4 immune-mediated adverse reactions involving a major organ
- **Infections.** Severe infections, including fatal cases, have occurred
- **Infusion-related reactions.** Severe or life-threatening infusion-related reactions have occurred. Permanently discontinue TECENTRIQ in patients with Grade 3 or 4 infusion-related reactions
- **Embryo-fetal toxicity.** TECENTRIQ can cause fetal harm in pregnant women. Verify pregnancy status prior to initiating TECENTRIQ. Advise females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TECENTRIQ and for at least 5 months after the last dose
- Advise female patients not to breastfeed while taking TECENTRIQ and for at least 5 months after the last dose

Most Common Adverse Reactions

The most common adverse reactions (rate ≥20%) in patients who received TECENTRIQ alone were fatigue/asthenia (48%), decreased appetite (25%), nausea (24%), cough (22%), and dyspnea (22%).

The most common adverse reactions (rate ≥20%) in patients who received TECENTRIQ in combination with other antineoplastic drugs for NSCLC and SCLC were fatigue/asthenia (49%), nausea (38%), alopecia (35%), constipation (29%), diarrhea (28%), and decreased appetite (27%).

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see accompanying full Prescribing Information for additional Important Safety Information.

For more information, please contact your BioOncology Field Reimbursement Manager or Genentech Oncology Access Solutions for TECENTRIQ by calling 1-866-422-2377 or by visiting https://www.genentech-access.com/TECENTRIQ.


All registered trademarks are the property of their respective owners.